Education
About Us
Working with TipRanks
Follow Us
HilleVax, Inc (HLVX)
NASDAQ:HLVX
HLVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.41 - $16.31
Previous CloseN/A
Volume43.09K
Average Volume (3M)137.82K
Market Cap
$79.19M
Enterprise Value-$44.28M
Total Cash (Recent Filing)$457.00K
Total Debt (Recent Filing)$3.02M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Jun 04, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding50,141,064
10 Day Avg. Volume135,736
30 Day Avg. Volume137,816
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$2.00Price Target Upside37.93% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
HilleVax, Inc News
PremiumCompany Announcements
HilleVax Reports 2024 Financial Results Amid Strategic Exploration
PremiumPre-Earnings
Is HLVX a Buy, Before Earnings?
PremiumCompany Announcements
HilleVax, Inc. Announces Workforce Reduction and Leadership Changes
PremiumCompany Announcements
HilleVax Reports Q3 Financial Results Amid Strategic Planning
---
Bulls Say, Bears Say
Bulls Say
Debt ManagementNet Debt to Total Capital is 0%, indicating no debt burden.
Financial StabilityThe company reported a cash balance of $189.3M, which was 97% above the company’s current market cap of approx. $96M.
Pipeline DevelopmentThe company is exploring prospective continued development of its norovirus vaccine candidates that could be relevant for adult patients.
Bears Say
Clinical Trial FailureThe Phase 2B NEST-IN1 trial for HIL-214 in norovirus failed to demonstrate effect across both primary and secondary endpoints, resulting in the discontinued development of HIL-214 in the infant population.
Cost ManagementManagement continues to wind down costs following the NEST-IN1 infant trial failure.
Efficacy ConcernsThe former infant study failed to meet its primary efficacy endpoint assessing moderate or severe acute gastroenteritis due to the GI.1 or GII.4 norovirus genotypes and resulted in no secondary endpoint benefit.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HLVX FAQ
What was HilleVax, Inc’s price range in the past 12 months?
HilleVax, Inc lowest stock price was $1.41 and its highest was $16.30 in the past 12 months.
What is HilleVax, Inc’s market cap?
HilleVax, Inc’s market cap is $79.19M.
When is HilleVax, Inc’s upcoming earnings report date?
HilleVax, Inc’s upcoming earnings report date is Jun 04, 2025 which is in 63 days.
How were HilleVax, Inc’s earnings last quarter?
HilleVax, Inc released its earnings results on Mar 28, 2025. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.327 by -$0.353.
Is HilleVax, Inc overvalued?
According to Wall Street analysts HilleVax, Inc’s price is currently Undervalued.
Does HilleVax, Inc pay dividends?
HilleVax, Inc does not currently pay dividends.
What is HilleVax, Inc’s EPS estimate?
HilleVax, Inc’s EPS estimate is -0.32.
How many shares outstanding does HilleVax, Inc have?
HilleVax, Inc has 50,141,064 shares outstanding.
What happened to HilleVax, Inc’s price movement after its last earnings report?
HilleVax, Inc reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.327. Following the earnings report the stock price went down -8.805%.
Which hedge fund is a major shareholder of HilleVax, Inc?
Currently, no hedge funds are holding shares in HLVX
---
HilleVax, Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (37.93% Upside)
$2.00 (37.93% Upside)
Hedge Fund Trend
Decreased
By 31.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $63.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.28%
12-Months-Change
Fundamentals
Return on Equity
-70.13%
Trailing 12-Months
Asset Growth
-44.06%
Trailing 12-Months
Company Description
HilleVax, Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
---
HLVX Stock 12 Month Forecast
Average Price Target
$2.00
▲(37.93% Upside)
Technical Analysis
Best Analysts Covering HLVX
1 Year
Unknown AnalystJ.P. Morgan
Not Ranked
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
reiterated a buy rating 11 months ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
---